Shares of ALX Oncology Holdings Inc. (Nasdaq: ALXO) surged by more than 100% in pre-market trading after the company unveiled positive interim Phase 2 data from the ASPEN-06 clinical trial evaluating its CD47 blocking therapeutic evorpacept in combination with trastuzumab, CYRAMZA, and paclitaxel to treat patients with HER2-positive gastric/gastroesophageal junction (GEJ) cancer.

The interim analysis, based on results from 54 randomized patients with second and third-line gastric/GEJ cancer, showed a remarkable confirmed overall response rate of 52% for the evorpacept combination treatment compared to 22% for the control treatment.

According to ALX Oncology, evorpacept became the first CD47 blocker to show activity in a global randomized study in solid tumors

$ALXO was trading at $10.99 in pre-market, reflecting a remarkable increase of $6.18 (+128.48%) 

In other news, McCormick & Company, Incorporated (NYSE: MKC), a renowned spice and flavorings manufacturer, reported third-quarter fiscal 2023 adjusted earnings of $0.65 per share, in line with the consensus EPS estimate of $0.65. However, the company's quarterly sales fell slightly short of expectations at $1.69 billion, while analysts had projected revenue of $1.70 billion.

Looking forward to full-year fiscal 2023, McCormick expects adjusted EPS to range from $2.62 to $2.67, compared to the consensus estimate of $2.64.

In pre-market, $MKC was trading at $72.50, down $2.22 (-2.97%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)